A phase Ib/II study to determine the safety and efficacy of eprenetapopt (APR-246) with AZA in patients with TP53-mutant MDS or AML with a low percentage of blasts has recently been published, with highly promising results [55] (Table 2). The gene discussed is TP53; the disease is acute myeloid leukemia.